We are live on
!
Find out more
EU
Emory University Portfolio holdings
AUM
$160M
1-Year Est. Return
8.57%
This Fund
S&P 500
This Quarter
Est. Return
-14.41%
1 Year Est. Return
+8.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$127M
AUM Growth
-$25.9M
(-17%)
Cap. Flow
-$1.77M
Cap. Flow
% of AUM
-1.39%
Top 10 Holdings %
Top 10 Hldgs %
51.19%
Holding
54
New
8
Increased
16
Reduced
16
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$2.47M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$2.42M |
| 3 |
AMRN
Amarin Corp
AMRN
|
+$2.36M |
| 4 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$2.34M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
+$2.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DBVT
DBV Technologies
DBVT
|
+$3.11M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$2.96M |
| 3 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
+$2.64M |
| 4 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$2.58M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
+$2.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 48.32% |
| 2 | Financials | 34.37% |
| 3 | Consumer Discretionary | 6.74% |
| 4 | Industrials | 2.63% |
| 5 | Real Estate | 1.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
26
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.92M | 1.51% |
19,667
-3,348
| -15% | -$396K |
|
|
DRNA
27
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $1.84M | 1.45% |
+172,524
| New | +$2.27M |
|
28
Solid Biosciences
SLDB
$974M
| $1.84M | 1.45% |
4,581
-71
| -2% | -$33.4K |
|
29
Neurocrine Biosciences
NBIX
$15.3B
| $1.81M | 1.42% |
25,289
+1,804
| +8% | +$173K |
|
|
AMRN
30
Amarin Corp
AMRN
$299M
| $1.76M | 1.39% |
+6,470
| New | +$2.36M |
|
|
IMMU
31
DELISTED
Immunomedics Inc
IMMU
| $1.76M | 1.38% |
123,101
-2,151
| -2% | -$42.7K |
|
32
CBRE Group
CBRE
$44B
| $1.74M | 1.37% |
43,532
-2,085
| -5% | -$86.2K |
|
33
Morgan Stanley
MS
$343B
| $1.7M | 1.34% |
42,743
-1,988
| -4% | -$86.8K |
|
34
KKR & Co
KKR
$103B
| $1.69M | 1.33% |
85,941
+1,455
| +2% | +$33.3K |
|
35
Seagate
STX
$209B
| $1.69M | 1.33% |
43,663
+4,084
| +10% | +$172K |
|
36
Trinity Industries
TRN
$2.34B
| $1.68M | 1.33% |
81,739
-70
| -0.1% | -$1.61K |
|
37
Armstrong World Industries
AWI
$7.68B
| $1.66M | 1.31% |
28,514
-2,478
| -8% | -$158K |
|
38
Citigroup
C
$233B
| $1.51M | 1.19% |
29,095
-1,511
| -5% | -$95.7K |
|
39
SLM Corp
SLM
$5.22B
| $1.49M | 1.17% |
179,133
-5,680
| -3% | -$56.5K |
|
40
Bread Financial
BFH
$4.51B
| $1.43M | 1.12% |
11,915
+659
| +6% | +$103K |
|
|
LJPC
41
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $1.41M | 1.11% |
149,013
+31,537
| +27% | +$475K |
|
42
Bausch Health
BHC
$2.37B
| $1.36M | 1.07% |
+73,529
| New | +$1.75M |
|
|
SMC
43
Summit Midstream
SMC
$480M
| $880K | 0.69% |
5,837
| – | – |
|
44
Cocrystal Pharma
COCP
$15.2M
| $550K | 0.43% |
12,743
| – | – |
|
45
Amazon
AMZN
$2.86T
| $237K | 0.19% |
3,160
| – | – |
|
46
State Street SPDR S&P 500 ETF Trust
SPY
$815B
| $218K | 0.17% |
872
| – | – |
|
|
DBVT
47
DBV Technologies
DBVT
$882M
| – | – |
-13,845
| Closed | -$3.11M |
|
|
SAGE
48
DELISTED
Sage Therapeutics
SAGE
| – | – |
-17,998
| Closed | -$2.54M |
|
49
TG Therapeutics
TGTX
$7.34B
| – | – |
-231,989
| Closed | -$1.3M |
|
|
MNTA
50
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| – | – |
-98,084
| Closed | -$2.58M |
|
Similar funds
SGCM
LCA
SMF
PCC
VCIM
RCWM
BFAG
SLG
Emory University's Q4 2018 Portfolio in Review
As of Q4 2018, Emory University held 54 positions worth $127M, down 17% from $153M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Emory University's Q4 2018 filing shows 8 new, 16 increased, 16 reduced and 8 closed positions. Its largest new stake was BioCryst Pharmaceuticals: 317,745 shares worth $2.56M. The largest sale was DBV Technologies, an estimated $3.11M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, down from 50% a quarter earlier, followed by Financials and Consumer Discretionary.
- Emory University's largest Q4 2018 buy was BioCryst Pharmaceuticals: 317,745 shares worth $2.56M.
- Emory University added most to Madrigal Pharmaceuticals in Q4 2018, an estimated $874K increase.
- Emory University's biggest Q4 2018 reduction was Acadia Pharmaceuticals, cutting an estimated $1.44M.
- Emory University fully exited DBV Technologies in Q4 2018, selling an estimated $3.11M.
- Emory University's ten largest holdings make up 51% of its $127M portfolio in Q4 2018.
- Emory University opened 8 new positions and closed 8 in Q4 2018.
- Emory University's portfolio value fell 17% quarter-over-quarter to $127M.
Based on Emory University's 13F filing for Q4 2018, filed 12 Feb 2019.